1. SN-38 covalently coupled to antibody to human trophoblast cell surface antigen(TROP2), a glycoprotein found on several solid tumors135–1372. Objective response rates in phase II clinical trials in triple negative breastcancer (30%)138,139, non-small cell lung cancer (19%)140, and metastatic smallcell lung cancer (14%)1413. Synergizes with PARP inhibitors in triple-negative breast cancer independent ofBRCA1/2 mutation status142. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.